Ibru+ven x 16➡️ibru+obinu x 6 if MRD+ (if uMRD-, obs) #ASH24: - 84 pts, 7% TP53mut, 57% very high CLL-IPI - 21% uMRD➡️obs: 2-yr PFS 94% - 79% MRD+➡️IO intensification: 60% achieved subsequent uMRD, 2-yr PFS 92% 60% of all pts achieved uMRD. Time-limited tx strategies ftw! #leusm

#ASH24 Circulating Tumor Cells (CTC) as a biomarker for TE NDMM in Perseus trial (D-VRd vs. VRd) -CTC is an independent prognostic factor -HR cytogenetics + CTC => dismal outcome #mmsm #bmtsm ash.confex.com/ash/2024/web...

ASCO has released an updated Rapid Recommendation for stage III NSCLC in JCO Oncology Practice. Update now includes targeted therapy: consolidation osimertinib after chemoradiation for #EGFR NSCLC, adjuvant osimertinib or alectinib for resected EGFR or ALK NSCLC. #LCSM ascopubs.org/doi/10.1200/...

@szusmani.bsky.social At PCUH(Pakistan PSH).....Will try to get his full presentation very soon.thoughts provoking talk...we are blessed ,

Updated breast cancer algorthim with updated data....

@medihumdani.bsky.social Great Talk by Dr.Mehdi Hamdini bhai at PCUH (PSH) .Very informative talk. Can we have the whole ppt?

Nice algorithmic approach

Nice summary

Looks much similar to X. Hopefully, it will be a great experience with skyblue. Nice transition from X to sky blue.